Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.69 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.67 |
| ▸ | ATR | Q13535 | 2/20 | 0.58 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.57 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.54 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.54 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190118 | 0.89 | HPGDS (0.71) | HPGDSUSP30BAZ2BPRKAB2PRKAG1 | |
| SCHEMBL2073316 | 0.88 | HPGDS (0.58) | HPGDSUSP30ATRNPC1RAB9A | |
| SCHEMBL12775215 | 0.88 | HPGDS (0.58) | HPGDSUSP30ATRGABRA5NPC1 | |
| SCHEMBL2072921 | 0.87 | HPGDS (0.74) | HPGDSUSP30ATRGABRA5DYRK1A | |
| SCHEMBL4636340 | 0.86 | GABRA5 (0.55) | HPGDSUSP30ATRGABRA5PRKAB2 | |
| SCHEMBL12776620 | 0.86 | HPGDS (0.53) | HPGDSUSP30ATRGABRA5PRKAB2 | |
| SCHEMBL2071408 | 0.85 | HPGDS (0.66) | HPGDSUSP30BAZ2BPRKAB2PRKAG1 | |
| SCHEMBL5053993 | 0.85 | HPGDS (0.75) | HPGDSUSP30ATRGABRA5MEN1 | |
| SCHEMBL12775220 | 0.85 | HPGDS (0.60) | HPGDSUSP30ATRGABRA5AXL | |
| SCHEMBL2073964 | 0.84 | PRKAA2 (0.78) | HPGDSUSP30GABRA5PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2129660-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | HPGDS 984/4885USP30 4416/4885ATR 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.